Immunogen management is failing and you are too busy (see list below) to protect the shareholders from IMGN's underperforming and self-serving management. With all due respect, the IMGN shareholders deserve more attention and would be better served if you resign.
I am a shareholder, I have been following the company and investing off and on for 20+ years. I could generate a long list of the management's failures, but the bottom line is the stock price is $11+ and that's unacceptable after 20+ years in business and in this bull market for biotech (see rival SGEN's performance).
In addition to his financial experience, Mr. McCluski serves as Chairman of the Board of PACS Industries, Inc. (a Deltapoint portfolio company) and ImmunoGen, Inc. (IMGN). Additionally, he serves on the Board of American Aerogel Corp. (a private company) and Lasermax, Inc. (a private company). He also served on the Board of Standard Microsystems Corp. (acquired by Microchip Technology Inc.), prior to the sale of that company. He currently serves as an operating director of DeltaPoint Capital Management, LLC, a private equity group, on the Advisory Board of the Wilmot Cancer Center of the University of Rochester and as a trustee at Ithaca College.
My inquiry to you, is what constitute long term, weak $$$$, because it feels like a losing bet, and this game one shouldnt marry a bet. Should I take my lumps and buy another loser bet, or buy high end shoes n chocolate. Is any news on this co. a non-event????
Its horrible to see this bet resemble 'death by a 1000 cuts'
kid miserable - long term disclosure #$%$ bet,
hold winners, sell losers,,, my would runneth over if I practised that